Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab PK via Auto-Injector or Prefilled Syringe in SLE
NCT02041091Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tabalumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Tabalumab After Loading Dose at Day 14 and Area Under the Concentration Time Curve From Time 0 to 14 Days. Started Jan 2014; status: terminated.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02041091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041091.